Paraneoplastic Autoantibody Interpretation

A negative paraneoplastic autoantibody result does not exclude the presence of all clinically significant antibodies. If clinically appropriate, testing with a phenotype-specific panel—such as for encephalopathy, dementia, myelopathy, or axonal neuropathy—should be considered.

A positive paraneoplastic antibody (Paraneoplastic Ab) result suggests the presence of an autoimmune response that may be associated with an underlying malignancy, even if the cancer has not yet been diagnosed.

Here’s what a positive result typically indicates:

1. Possible Paraneoplastic Neurological Syndrome (PNS):
   The antibodies target neural tissues and are often associated with neurological symptoms. These syndromes are not caused by direct tumor invasion but by the immune system's response to a tumor.

2. High suspicion for an occult malignancy:
   Certain antibodies are strongly associated with specific cancers. For example:

   • Anti-Hu (ANNA-1): Often linked to small cell lung cancer.

   • Anti-Yo (PCA-1): Commonly associated with breast or gynecological cancers.

   • Anti-Ri (ANNA-2): Linked to breast or lung cancer.

   • Anti-Ma, CV2/CRMP5, Amphiphysin, etc., are also associated with various tumors.

3. Autoimmune neurological disorders with or without cancer:
   Some paraneoplastic antibodies can be present in patients with autoimmune neurological disorders even when no malignancy is found. In these cases, ongoing surveillance may be recommended.

4. Need for further clinical correlation and cancer screening:
   A positive result should prompt a comprehensive evaluation, including imaging and possibly referral to oncology and neurology, to look for underlying malignancy and to assess neurological function.

In summary, a positive paraneoplastic antibody result indicates a potential autoimmune reaction that may be linked to cancer, warranting further diagnostic workup.